June 28, 2023
Otsuka Pharmaceutical said on June 27 that its atypical antipsychotic Rexulti (brexpiprazole) hit the main goal in a domestic PIII trial targeting an additional indication of agitation associated with Alzheimer’s dementia. The company plans to seek the drug’s label expansion...read more